BioInvent hit with clinical hold on midstage myeloma test

Swedish biotech BioInvent (STO:BINV) has been told by the FDA to stop dosing multiple myeloma patients in its Phase II test for BI-505 due to safety concerns.

In a brief update, the biotech said the full clinical hold was prompted by an “adverse cardiopulmonary event” in the study--although no further details were given as its exec team awaits a written confirmation of the halt.

The BI-505 test is being carried out by BioInvent with investigators at the University of Pennsylvania, and was geared up to assess the ability of BI-505 to see if it could prevent or delay relapse of multiple myeloma in patients undergoing autologous stem cell transplantation with high-dose melphalan.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

“BioInvent will analyse the possibility to obtain release of the clinical hold and markets will be updated when there is further information to report,” the company said.

It is also working on BI-1206, in Phase I/II for non-Hodgkin’s lymphoma and chronic lymphatic leukemia, and has tie-ups with a number of academic centers and pharmas, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma.

BioInvent, listed on the Stockholm market, saw its shares plummet 22% on the news this morning.

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.